NRAS and melanoma: Unexpectedly, more NRAS melanomas, that are less sensitive to clinical RAF and MEK inhibitors46, were found in the sensitive group compared to other groups (Seven NRAS mutant melanoma cell lines were found to be sensitive, compared to four melanoma cell lines that were partially sensitive and three melanoma cell lines that were completely unresponsive and resistant to EPE peptide) (Fig. 1).